- RESEARCH HIGHLIGHT
New route to target RAS
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41573-024-00082-8
References
Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature https://doi.org/10.1038/s41586-024-07205-6 (2024)
Wasko, U. N. et al. Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature https://doi.org/10.1038/s41586-024-07379-z (2024)